Japan pins hopes on Israeli stem-cell tech

  Four years after Japan’s Fukushima nuclear plant disaster, Fukushima Medical University’s Global Medical Science Center has signed a memorandum of understanding with Israel’s Pluristem Therapeutics More...

Pluristem’s Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints

Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR), a leading developer of placenta-based cell therapies, today announced top-line results from its Phase I/II clinical trial testing the safety More...